Elevai Labs, Inc. Common Stock (NASDAQ:ELAB) — Market Cap & Net Worth
Market Cap & Net Worth: Elevai Labs, Inc. Common Stock (ELAB)
Elevai Labs, Inc. Common Stock (NASDAQ:ELAB) has a market capitalization of $3.74 Million ($3.74 Million) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #29212 globally and #5967 in its home market, demonstrating a -1.65% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Elevai Labs, Inc. Common Stock's stock price $4.77 by its total outstanding shares 809579 (809.58K). Also see ELAB asset base for a full breakdown of the balance sheet.
Elevai Labs, Inc. Common Stock Market Cap History: 2023 to 2026
Elevai Labs, Inc. Common Stock's market capitalization history from 2023 to 2026. Data shows change from $295.98 Million to $3.86 Million (-82.75% CAGR). Also see ELAB cash flow conversion for how efficiently the company converts equity into cash flow.
Index Memberships
Elevai Labs, Inc. Common Stock is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Composite
IXIC
|
$41.69 Trillion | 0.00% | #2716 of 3165 |
Weight: Elevai Labs, Inc. Common Stock's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Elevai Labs, Inc. Common Stock Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Elevai Labs, Inc. Common Stock's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Elevai Labs, Inc. Common Stock share price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
2.03x
Elevai Labs, Inc. Common Stock's market cap is 2.03 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2023 | $295.98 Million | $1.71 Million | -$4.30 Million | 172.83x | N/A |
| 2024 | $1.85 Million | $2.47 Million | -$6.25 Million | 0.75x | N/A |
| 2025 | $1.20 Million | $590.08K | -$7.71 Million | 2.03x | N/A |
Competitor Companies of ELAB by Market Capitalization
Companies near Elevai Labs, Inc. Common Stock in the global market cap rankings as of September 18, 2026. Review Elevai Labs, Inc. Common Stock (ELAB) tangible equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Elevai Labs, Inc. Common Stock by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #187 globally with a market cap of $130.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.34 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.87 Billion USD ( AU$84.62 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #187 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.09 Billion | $513.26 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.34 Billion | $774.61 |
| #457 | CSL Ltd | AU:CSL | $59.87 Billion | AU$174.41 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $145.62 |
Elevai Labs, Inc. Common Stock Historical Marketcap From 2023 to 2026
Between 2023 and today, Elevai Labs, Inc. Common Stock's market cap moved from $295.98 Million to $ 3.86 Million, with a yearly change of -82.75%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $3.86 Million | +222.30% |
| 2025 | $1.20 Million | -35.37% |
| 2024 | $1.85 Million | -99.37% |
| 2023 | $295.98 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 17th, 2026 the market cap of Elevai Labs, Inc. Common Stock was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $3.74 Million USD |
| MoneyControl | $3.74 Million USD |
| MarketWatch | $3.74 Million USD |
| marketcap.company | $3.74 Million USD |
| Reuters | $3.74 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Elevai Labs, Inc. Common Stock
PMGC Holdings Inc., a biopharmaceutical company, focuses on the development and acquisition of aesthetic medicines and therapeutic products. It operates through three segments: corporate, treasury and biosciences; IT packaging solutions; and precision engineering and machining. The company's lead product includes EL-22, a first-in-class engineered probiotic approach to address obesity's pressing … Read more